Abstract
Related Adhesion Focal Tyrosine Kinase (RAFTK; also known as Pyk2), is a member of the Focal Adhesion Kinase (FAK) subfamily and is activated by TNFα, UV light and increases in intracellular calcium levels. However, the function of RAFTK remains largely unknown. Our previous studies demonstrated that treatment with dexamethasone (Dex), ionizing radiation (IR), and anti-Fas mAb induces apoptosis in multiple myeloma (MM) cells. In the present study, we examined the potential role of RAFTK during induction of apoptosis in human MM cells triggered by these three stimuli. Dex-induced apoptosis, in contrast to apoptosis triggered by anti-Fas mAb or IR, is associated with activation of RAFTK. Transient overexpression of RAFTK wild type (RAFTK WT) induces apoptosis, whereas transient overexpression of Kinase inactive RAFTK (RAFTK K-M) blocks Dex-induced apoptosis. In contrast, transient overexpression of RAFTK K-M has no effect on apoptosis triggered by IR or Fas. In Dex-resistant cells, Dex does not trigger either RAFTK activation or apoptosis. Finally, interleukin-6 (IL-6), a known survival factor for MM cells, inhibits both activation of RAFTK and apoptosis of MM.1S cells triggered by Dex. Our studies therefore demonstrate Dex-induced RAFTK-dependent, and IR or Fas induced RAFTK-independent apoptotic signaling cascades in MM cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Astier A, Avraham H, Manie SN, Groopman J, Canty T, Avraham S and Freedman AS. . 1997a J. Biol. Chem. 272: 228–232.
Asteir A, Manie SN, Avraham H, Hirai H, Law SF, Zhang Y, Golemis EA, Yigong F, Druker BJ, Hagayeghi, Freedman AS and Avraham S. . 1997b J. Biol. Chem. 272: 19719–19724.
Avraham E, London R, Fu Y, Ota S, Hiregowdara J, Li S, Jiang S, Pastroz JM, White RA, Groopman JE and Avraham H. . 1995 J. Biol. Chem. 270: 27742–27751.
Avraham S and Avraham H. . 1997 Leuk & Lymph. 27: 247–256.
Berg NN and Ostergaard HL. . 1997 J. Immunol. 159: 1753–1757.
Chauhan D, Kharbanda SM, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW and Anderson KC. . 1997b Blood 89: 227–234.
Chauhan D, Pandey P, Ogata A, Urashima M, Teoh G, Kharbanda SM and Anderson KC. . 1997a Oncogene 15: 837–843.
Chauhan D, Pandey P, Ogata A, Teoh G, Krett N, Halgren R, Rosen ST, Kufe DW, Kharbanda SM and Anderson KC. . 1997c J. Biol. Chem. 272: 29995–29997.
Chauhan D, Kharbanda S, Urashima M, Malik N, Frank D, Kufe DW and Anderson KC. . 1995 J. Exp. Med. 182: 1801–1806.
Derkinderen P, Siciliano J, Toutant M and Girault JA. . 1998 Euro. J. Neuro. 10: 1667–1675.
Dikic I, Dikic I and Schlessinger J. . 1998 J. Biol. Chem. 23: 14301–14308.
Hamel W, Dazin P and Israel MA. . 1996 Cytometry 25: 173–181.
Hardin J, Macleod S, Grigorieva I, Chang R, Barlogie B, Xiao H and Epstein J. . 1994 Blood 84: 3063–3071.
Hardin JA, Sherr DH, DeMaria MA and Lopez PA. . 1992 J. Immunol. Methods. 154: 99–107.
Hiregowdara D, Avraham H, Fu Y, London R and Avraham S. . 1997 J. Biol. Chem. 272: 10804–10810.
Klein B, Zhang XG, Lu ZY and Bataille R. . 1995 Blood 85: 863–872.
Lev SH, Moreno R, Martinez P, Canoll E, Peles JM, Musacchio JM, Plowman GO, Rudy B and Schlessinger J. . 1995 Nature 376: 737–745.
Li Xiong Dy RC, Cance WG, Graves LM and Earp HS. . 1999 J. Biol. Chem. 274: 8917–8924.
Pandey P, Avraham S, Place A, Kumar V, Majumder PK, Cheng K, Nakazawa A, Saxena S and Kharbanda S. . 1999 J. Biol. Chem. 274: 8618–8623.
Pandey P, Avraham S, Kumar S, Nakazawa A, Place A, Ghanem L, Rana A, Kumar V, Majumder PK, Avraham H, Davis R and Kharbanda S. . 1999 J. Biol. Chem. 274: 10140–10144.
Salgia R, Avraham S, Pisick E, Li J, Raja S, Greenfield E, Sattler M, Avraham H and Griffin JD. . 1996 J. Biol. Chem. 271: 31222–31226.
Sasaki H, Nagura K, Ishimo M, Tobioka H, Kotani K and Sasaki T. . 1995 J. Biol. Chem. 270: 21206–21219.
Swanson KD, Reigh C and Landreth GE. . 1998 J. Biol. Chem. 273: 19965–19971.
Tokiwa G, Dikic I, Lev S and Schlessinger J. . 1996 Science 273: 792–794.
Tsuchida M, Knechtle SJ and Hamawy MM. . 1999 J. Biol. Chem. 274: 6735–6740.
Thornberry AT, Rosen A and Nicholson DW. . 1997 In: Kaufmann SH (ed). Apoptosis. Academic Press: San Diego, CA p. 155.
Verheij M, Bose R, Lin X-H, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z and Kolesnick RN. . 1996 Nature 380: 75–79.
Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME. . 1995 Science 270: 1326–1331.
Xiong WC and Parsons TJ. . 1997 J. Cell. Biol. 138: 529–539.
Xu Fu, Sharma S, Ganer A, Tu Y, Raitano A, Sawyers C and Lichtenstein A. . 1998 Blood 92: 241–251.
Yu H, Li X, Marchetto GS, Hunter D, Calvo B, Dawson TL, Wilm M, Anderegg RJ, Graves LM and Earp HS. . 1996 J. Biol. Chem. 271: 29993–29998.
Acknowledgements
We thank Dr Hawa Avraham for anti-RAFTK Ab; for GFP-RAFTK, RAFTK K457M (K-M), RAFTK Y402F, and RAFTK wild type (WT) constructs; and for critical reading of the manuscript. Drs Erica Golemis and Arnold Freedman kindly provided the GST-HEF constructs. This investigation was supported by PHS grants CA50947 (K Anderson) and CA75216 (S Kharbanda) awarded by the National Cancer Institute, a Kathy Giusti Multiple Myeloma Research Foundation Fellowship (D Chauhan), and DHHS grant HL55445 (S Avraham). Hervé Husson is supported by the Association pour la Recherche sur le Cancer (ARC).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chauhan, D., Hideshima, T., Pandey, P. et al. RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene 18, 6733–6740 (1999). https://doi.org/10.1038/sj.onc.1203082
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203082
Keywords
This article is cited by
-
Glucocorticoid Excess in Bone and Muscle
Clinical Reviews in Bone and Mineral Metabolism (2018)
-
Osteocytes and Their Messengers as Targets for the Treatment of Multiple Myeloma
Clinical Reviews in Bone and Mineral Metabolism (2017)
-
Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma
Oncogene (2016)
-
Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance
Archives of Pharmacal Research (2015)
-
The kinase Pyk2 is involved in renal fibrosis by means of mechanical stretch–induced growth factor expression in renal tubules
Kidney International (2012)